Information Provided By:
Fly News Breaks for August 14, 2017
DMPI
Aug 14, 2017 | 13:39 EDT
Maxim analyst Jason McCarthy downgraded DelMar Pharmaceuticals to Hold from Buy saying he sees "significant overhangs" in micro-caps like DelMar to raise the required capital to complete clinical studies. DelMar didn't raise enough capital in its last deal, leaving the company "between a rock and a hard place," the analyst tells investors in an intraday research note. He removed his previous price target of $11.
News For DMPI From the Last 2 Days
There are no results for your query DMPI